Correcting the drug development paradigm for glioblastoma requires serial tissue sampling-Reference-Cited by-同舟云学术

Correcting the drug development paradigm for glioblastoma requires serial tissue sampling

Published:2023-07-24 Issue:10 Volume:29 Page:2402-2405
ISSN:1078-8956
Container-title:Nature Medicine
language:en
Short-container-title:Nat Med

Author:

Singh Kirit^ORCID,Hotchkiss Kelly M.,Parney Ian F.^ORCID,De Groot John,Sahebjam Solmaz^ORCID,Sanai Nader^ORCID,Platten Michael^ORCID,Galanis Evanthia,Lim Michael^ORCID,Wen Patrick Y.,Minniti Giuseppe,Colman Howard,Cloughesy Timothy F.^ORCID,Mehta Minesh P.,Geurts Marjolein,Arrillaga-Romany Isabel,Desjardins Annick^ORCID,Tanner Kirk,Short Susan^ORCID,Arons David,Duke Elizabeth,Wick Wolfgang^ORCID,Bagley Stephen J.^ORCID,Ashley David M.,Kumthekar Priya,Verhaak Roel^ORCID,Chalmers Anthony J.^ORCID,Patel Anoop P.,Watts Colin^ORCID,Fecci Peter E.^ORCID,Batchelor Tracy T.,Weller Michael^ORCID,Vogelbaum Michael A.,Preusser Matthias^ORCID,Berger Mitchel S.,Khasraw Mustafa^ORCID

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://www.nature.com/articles/s41591-023-02464-8.pdf

Reference15 articles.

1. Bagley, S. J. et al. Clin. Cancer Res. 28, 594–602 (2021).

2. Patel, A. P. et al. Science 344, 1396 (2014).

3. Pokorny, J. L. et al. Clin. Cancer Res. 21, 1916–1924 (2015).

4. Sanai, N. et al. Clin. Cancer Res. 24, 3820–3828 (2018).

5. Reardon, D. A. et al. JAMA Oncol. 6, 1003–1010 (2020).

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The oncological role of resection in newly diagnosed diffuse adult-type glioma defined by the WHO 2021 classification: a Review by the RANO resect group;The Lancet Oncology;2024-09

2. Surgical window of opportunity trial reveals mechanisms of response and resistance to navtemadlin (KRT-232) in patients with recurrent glioblastoma;2024-08-14

3. Stemness, invasion, and immunosuppression modulation in recurrent glioblastoma using nanotherapy;WIREs Nanomedicine and Nanobiotechnology;2024-07

4. Proteasome inhibition for glioblastoma: Lessons learned and new opportunities;Neuro-Oncology;2024-06-27

5. Evolocumab as an immunomodulator in glioma: A window of opportunity trial evaluating PCSK9 inhibition to enhance surface MHC-I on tumor;2024-06-20